Trialbee Secures €11 million in Funding to Scale Digital Patient Trial Recruitment and Engagement Solutions

Trialbee announces the closure of an €11 million investment round to onboard strategic investor MTIP, the European specialist investor in Healthtech scale-up companies. Existing investors Industrifonden and Briban Invest also participated in the round.

Trialbee Celebrates Triple Digit Growth Year over Year

Company’s positive trajectory with revenue, partnerships, and customers to continue with a strong outlook in 2020

Trialbee announces strong sales results and a 10 yearlong patient engagement and retention assignment


Trialbee announces strong sales results in H1 2019 and the launch of a 10 yearlong assignment for its engagement and retention technology with one of the largest global pharmaceutical companies.

Trialbee, a leading technology company in the development of innovative software to reduce clinical trial recruitment timelines and increase the patient engagement experience, announces the appointment of Richard Thomas as its new member to its Board of Directors.

Trialbee delivered strong YoY sales result for its patient matching and engagement technology and exceeded its H1 2019 sales target by 26%. The sales uptake in H1 2019 is predominately driven by growth within the pharmaceutical customer segment. H1 has also demonstrated an increased interest among some of the leading global Contract Research Organizations, a trend the company believes will continue to develop. Sales in H1 is also indicating that customers are requesting to onboard Trialbee’s technology earlier in the drug development process, which is in line with Trialbee’s sales strategy. The technology platform is gaining more momentum as an embedded solution from clinical trial planning through the patient retention phase.

“We are pleased to note that our solutions are delivering demonstrable recruitment and retention efficiencies for our customers, which has advanced Trialbee to become an embedded healthcare partner with major clients, a key strategic driver for continued double digit growth.” Robert Molander, Chief Commercial Officer at Trialbee, said.

In addition to the strong sales result in H1, Trialbee was also successful in landing its longest engagement and retention assignment with one of the largest pharmaceutical companies. Trialbee’s engagement technology will follow more than 3,000 subjects over a 10-year period to support timely and accurate monitoring of questionnaire completeness. The assignment demonstrates the potential of the technology and future applications, but also the high value it delivers to patients and sponsors in securing reliable long-term study outcomes.

About Trialbee:

Trialbee is a world leading technology provider in patient matching and engagement, empowering patients to participate in clinical trials as a care option. Founded in 2010, Trialbee has continuously innovated patient-centric technology solutions for global clinical trials. Trialbee – Dedicated to patients; driven by science; and powered by data. For more information, visit and contact us at [email protected]


Press Contact:
Robert Grimm

+46(0)76-525 82 11
[email protected]

Investor Contact:
Daniel Spasic

Executive Chairman Trialbee
[email protected]

Meet us during OCT East Coast 2019, May 21-22

Meet Trialbee in King of Prussia, PA, during OCT East Coast 2019, May 21-22!

We are there to share our latest digital solutions and insights within patient recruitment and patient engagement. Please join us during our session on May 21 “Being a better recruitment partner to sites” and meet up with us during the conference. Contact Alicia Foley to book a meeting for the conference.

Read more about the conference here

Trialbee, World Vaccine Congress

Trialbee participates in World Vaccine Congress

Trialbee participates in World Vaccine Congress, Washington, April 14-17

Meet Trialbee in Washington for the World Vaccine Congress, R+D + Strategic partnering for the Global Vaccine Industry. Visit booth #223 to get the latest insights in digital solutions within recruitment and engagement which enables accelerated clinical research.

Read more about the World Vaccine Congress.

Trialbee and Linical Accelovance Group join forces

Trialbee and Linical Accelovance Group join forces to intergrate patient recruitment and retention services throughout the clinical trial execution process.

MALMÖ, SWEDEN and ROCKVILLE, MD. March 26, 2019.

Trialbee, a world leading technology provider in patient matching and engagement, and Linical Accelovance Group, a market-leading, midsized, global contract research organization (CRO), announce they will join forces to drive the next generation of digitally powered patient-centric clinical trials. Biopharma sponsors will now have access to a single point of contact delivering end-to-end next generation clinical trials, expediting clinical trial enrollment, retention and speed-to-market solutions.

By interlinking digital capability and global clinical trial execution into one end-to-end support chain, this partnership has what it takes to positively disrupt clinical research and accelerate patient access to new treatments and improved outcomes.

Patient-centricity is valuable to the entire clinical trial lifecycle. Patient and clinical data refine the feasibility process and help sharpen trial design. A digital recruitment strategy can then be deployed to reach the targeted patient population and enhance trial enrollment timelines. Furthermore, customized engagement solutions mitigate patient attrition, resulting in reduced site burden while maintaining data integrity, quality and project timelines.

“Trialbee drives clinical trial success by combining in depth knowledge of clinical trial design and our digital outreach expertise to identify, connect, engage and offer patients access to relevant trials. By addressing patient-specific needs in a relevant manner, we bridge the gap between willing patients and available clinical trials, manage expectations, and connect well-informed and already engaged patients with investigational sites. In partnership with Linical Accelovance Group, a clinical research operations leader providing flexible and pragmatic drug development services, we can jointly deliver a world class recruitment and engagement model across the entire trial lifecycle, resulting in on-time delivery of quality data,” said Lars-Olof Eriksson, CEO of Trialbee.

Vita Lanoce, CEO of Linical Accelovance Group, commented, “We are pleased to be at the forefront of developing new approaches to accelerate enrollment timelines by engaging patients and investigational sites to successfully deliver clinical research trials. As a global CRO, we have expertise designing and conducting clinical trials across many therapeutic areas and strong relationships with investigative sites. By layering our strengths with Trialbee’s technology, we can deliver a more powerful, integrated solution that assures a clear understanding of the patient journey, enhancing patient recruitment and retention, and, as a result, benefiting sponsors, sites, and the patients themselves.”

In the clinical research community, delivering a clinical trial successfully requires strict focus on well-known barriers. The same challenges still prevail; 11-30% of sites fail to recruit a single patient and as many as 50% of trials are delayed due to recruitment issues. The costs incurred because of delays are momentous, amounting to as much as $8 million per day, along with detrimental setbacks in access to cures. Even once a patient is enrolled, retention and protocol adherence are of the utmost importance for success. The reality is that 30% of enrolled patients will drop out over the course of a clinical study. The industry is yearning for innovative solutions to effectively recruit and retain patients in clinical trials.

About Trialbee:

Trialbee empowers patients worldwide with clinical trials as a care option through best-in-class digital patient matching and engagement solutions. Since its inception, Trialbee has continuously innovated patient-centric solutions for global clinical trials. Trialbee operates its technology globally from two locations in Sweden and the USA. Trialbee – Dedicated to patients; driven by science; and powered by data. For more information, contact [email protected].

About Linical Accelovance Group:

Linical Accelovance Group is a market-leading, midsized, global contract research organization with a significant footprint across North America, Europe and Asia-Pacific. With operations in more than 20 countries, Linical Accelovance Group is a full-service CRO uniquely capable of conducting large-scale, multinational studies, while delivering personalized, hands-on service. The organization’s areas of expertise include oncology, hematology, vaccines, CNS, and general medicine trials across Phases I-IV. Providing drug development services to pharmaceutical companies, biotechs, investigative sites and academic institutions, Linical Accelovance Group supports client needs by leveraging operational knowledge and patient recruitment strategies that result in successful clinical trials.

SCOPE Summit 2019

SCOPE Summit 2019

Meet us in Orlando, Florida during SCOPE Summit 2019, on Feb 18-21 where we will share our latest solutions and insights. Please contact Alicia Foley or Joe Buser to book a meeting.

Read more about SCOPE here.

Cookie Preferences


The Cloudflare cookie is used to identify individual clients behind a shared IP address and apply security settings on a per-client basis.


Google Analytics

Used by Google AdWords to re-engage visitors that are likely to enrol based on the visitor's online behaviour across websites.



Wordpress built-in cookies to keep user settings after page transitions.


Close your account?

Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?